Regulatory and Pipeline: H1 Milestones on track: Interim analyses for volixibat in PSC and in PBC expected in June of 2024. New Drug Application submission for CHENODAL in CTX on track for first half 2024. PFIC CHMP approval recommendation anticipated in the first half of 2024
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum data published in Lancet shows benefits of Livmarli in PFIC
- Mirum Pharmaceuticals initiated with a Buy at Stifel
- Mirum Pharmaceuticals participates in a conference call with JPMorgan
- Mirum Pharmaceuticals price target lowered to $43 from $44 at Leerink
- Mirum Pharmaceuticals’ Financial Uncertainty: FDA Approval Hurdles for Chenodal’s CTX Treatment
Questions or Comments about the article? Write to editor@tipranks.com